Teva Unit Takes Aim At Lilly In Chemo Patent Battle

Law360, New York (May 19, 2006, 12:00 AM EDT) -- In the latest move in a four-month long patent feud, Sicor Pharmaceuticals Inc., a unit of Teva Pharmaceuticals, is taking aim at Eli Lilly & Co. in federal court, seeking declaratory judgment that two of Sicor’s patents covering its Gemzar chemotherapy treatment are invalid and will not be infringed by Sicor’s generic version of the product.

The patents at issue in the case, U.S. Patent Nos. 4,808,614 and 5,464,826, cover injectable gemcitabine hydrochloride, which is used to treat certain kinds of cancer, including non-small cell lung...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.